We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Merck, Novartis and AstraZeneca
Read MoreHide Full Article
For Immediate Release
Chicago, IL – August 29, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Regeneron Pharmaceuticals (REGN - Free Report) , Merck & Co. (MRK - Free Report) , Novartis (NVS - Free Report) and AstraZeneca (AZN - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Oncology Market's Huge Potential Puts These Drug Stocks in Focus
The oncology treatment market has been experiencing significant growth due to various factors like the rising incidence of the disease, advancements in treatment modalities, personalized medicines, investments in research and developments, development in immunotherapy, growing healthcare infrastructure in emerging markets and collaborations between pharmaceutical companies and research institutions.
In this regard, investors can keep a tab on the likes of the stocks listed below. These players have made meaningful contributions in cancer treatment and the ability to generate huge business out of it.
Inside the Oncology Market's Huge Business Potential
Oncology spending is forecast to nearly double to $375 billion by 2027, per data from IQVIA Oncology Link, dated April 2023. The spending is forecast to grow materially across all types of cancers. According to Precedence Research, the global oncology market is expected to witness a CAGR of 8.8% from 2023 to 2032. Oncology, more than the rest of biotech, increasingly involves novel trial design.
There is a 100% increase in the number of new drugs approved for oncology from the year 2010 to 2021, per FDA data , quoted on Tema ETFs. FDA new drug approvals for Oncology in 2021 were the highest at 31%, followed by 10% for central nervous system and 8% for infectious diseases.
Not only this, with more growth in the cards, the investment opportunity has significantly expanded over the past decade due to a substantial rise in the number of newly listed oncology companies. There has been a boom in oncology-listed companies in the past decade. Moreover, nearly 25% of small biotech trade below net cash value, as quoted onTema ETFs' document.
Against this backdrop, below we highlight a few stocks that could be tracked to tap the immense investing potential in the oncology space.
Stocks in Focus
Regeneron Pharmaceuticals
Tarrytown, NY-based Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. Most recently, the company announced that the European Medicines Agency accepted to review the Marketing Authorization Application (MAA) for its pipeline candidate odronextamab.
Odronextamab is an investigational CD20xCD3 bispecific antibody designed to bridge CD20 on cancer cells with CD3-expressing T-cells to facilitate local T-cell activation and cancer-cell killing. The MAA is seeking approval of the candidate to treat adult patients with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL) who have progressed after at least two prior systemic therapies.
The Zacks Ranked #3 Merck & Co. boasts more than six blockbuster drugs in its portfolio, with PD-L1 inhibitor, Keytruda, approved for several types of cancer, alone accounting for around 46% of its pharmaceutical sales.
Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Keytruda may be Merck's biggest strength and a solid reason to own the stock. The stock has a moderate Value and Momentum Score of C each.
Novartis
Switzerland-based Novartis has one of the strongest and broadest portfolio of oncology drugs and generics, which has enabled it to maintain its dominant position as a top pharma company over the years. It continues to build depth in five core therapeutic areas (Cardiovascular, Immunology, Neuroscience, Solid Tumors and Hematology), strength in technology platforms (Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy and xRNA) and has a balanced geographic footprint.
Novartis' efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments has made it even more formidable in this space. The Zacks Rank #3 stock has an upbeat Value and Growth Score of B each.
AstraZeneca
The Zacks Rank #3 AstraZeneca plc, headquartered in London, UK, is one of the largest biopharmaceutical companies in the world.AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and others.
Just a month ago, AstraZeneca's management said that the company is "very encouraged" by interim data from a key lung cancer drug trial. The stock has an upbeat Value score of B.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Merck, Novartis and AstraZeneca
For Immediate Release
Chicago, IL – August 29, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Regeneron Pharmaceuticals (REGN - Free Report) , Merck & Co. (MRK - Free Report) , Novartis (NVS - Free Report) and AstraZeneca (AZN - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Oncology Market's Huge Potential Puts These Drug Stocks in Focus
The oncology treatment market has been experiencing significant growth due to various factors like the rising incidence of the disease, advancements in treatment modalities, personalized medicines, investments in research and developments, development in immunotherapy, growing healthcare infrastructure in emerging markets and collaborations between pharmaceutical companies and research institutions.
In this regard, investors can keep a tab on the likes of the stocks listed below. These players have made meaningful contributions in cancer treatment and the ability to generate huge business out of it.
Inside the Oncology Market's Huge Business Potential
Oncology spending is forecast to nearly double to $375 billion by 2027, per data from IQVIA Oncology Link, dated April 2023. The spending is forecast to grow materially across all types of cancers. According to Precedence Research, the global oncology market is expected to witness a CAGR of 8.8% from 2023 to 2032. Oncology, more than the rest of biotech, increasingly involves novel trial design.
There is a 100% increase in the number of new drugs approved for oncology from the year 2010 to 2021, per FDA data , quoted on Tema ETFs. FDA new drug approvals for Oncology in 2021 were the highest at 31%, followed by 10% for central nervous system and 8% for infectious diseases.
Not only this, with more growth in the cards, the investment opportunity has significantly expanded over the past decade due to a substantial rise in the number of newly listed oncology companies. There has been a boom in oncology-listed companies in the past decade. Moreover, nearly 25% of small biotech trade below net cash value, as quoted onTema ETFs' document.
Against this backdrop, below we highlight a few stocks that could be tracked to tap the immense investing potential in the oncology space.
Stocks in Focus
Regeneron Pharmaceuticals
Tarrytown, NY-based Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. Most recently, the company announced that the European Medicines Agency accepted to review the Marketing Authorization Application (MAA) for its pipeline candidate odronextamab.
Odronextamab is an investigational CD20xCD3 bispecific antibody designed to bridge CD20 on cancer cells with CD3-expressing T-cells to facilitate local T-cell activation and cancer-cell killing. The MAA is seeking approval of the candidate to treat adult patients with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL) who have progressed after at least two prior systemic therapies.
The stock has a Zacks Rank #3 (Hold) and an upbeat Momentum Score of A. You can see the complete list of today's Zacks #1 Rank stocks here.
Merck & Co.
The Zacks Ranked #3 Merck & Co. boasts more than six blockbuster drugs in its portfolio, with PD-L1 inhibitor, Keytruda, approved for several types of cancer, alone accounting for around 46% of its pharmaceutical sales.
Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Keytruda may be Merck's biggest strength and a solid reason to own the stock. The stock has a moderate Value and Momentum Score of C each.
Novartis
Switzerland-based Novartis has one of the strongest and broadest portfolio of oncology drugs and generics, which has enabled it to maintain its dominant position as a top pharma company over the years. It continues to build depth in five core therapeutic areas (Cardiovascular, Immunology, Neuroscience, Solid Tumors and Hematology), strength in technology platforms (Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy and xRNA) and has a balanced geographic footprint.
Novartis' efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments has made it even more formidable in this space. The Zacks Rank #3 stock has an upbeat Value and Growth Score of B each.
AstraZeneca
The Zacks Rank #3 AstraZeneca plc, headquartered in London, UK, is one of the largest biopharmaceutical companies in the world.AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and others.
Just a month ago, AstraZeneca's management said that the company is "very encouraged" by interim data from a key lung cancer drug trial. The stock has an upbeat Value score of B.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.